Sarcomas in TP53 germline mutation carriers: A review of the IARC TP53 database

Cancer

Volumn 118, Issue 5, 2012, Pages 1387-1396

  Ognjanovic, Simona ^a,b   Olivier, Magali ^c   Bergemann, Tracy L ^a   Hainaut, Pierre ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

End Results; Epidemiology; germline TP53 mutations; IARC TP53 Database; Li Fraumeni syndrome; sarcoma; Surveillance

Indexed keywords

PROTEIN P53;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER REGISTRY; CANCER SUSCEPTIBILITY; CAUCASIAN; CONTROLLED STUDY; EXON; FAMILIAL CANCER; FEMALE; FRAMESHIFT MUTATION; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DATABASE; GENETIC PREDISPOSITION; GENOTYPE PHENOTYPE CORRELATION; GERMLINE MUTATION; HETEROZYGOTE; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NONSENSE MUTATION; NUCLEIC ACID BASE SUBSTITUTION; ONSET AGE; OSTEOSARCOMA; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; RHABDOMYOSARCOMA; SARCOMA; SPLICING DEFECT; TP53 GENE;

AGE FACTORS; DATABASES, GENETIC; GENES, P53; GENETIC ASSOCIATION STUDIES; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; SARCOMA; SEER PROGRAM; UNITED STATES;

EID: 84857356609     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26390     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106-130.
2. Ries LAG, Melbert D, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2004 [based on the November 2006 SEER data submission, posted to the SEER web site 2007]. Bethesda, MD: National Cancer Institute; 2007.
3. Brennan MF,. Soft tissue sarcoma: advances in understanding and management. Surgeon. 2005; 3: 216-223. (Pubitemid 40932722)
4. Gurney JG, Young JL, Roffers SD, Smith MA, Bunin GR,. Soft Tissue Sarcomas. SEER Pediatric Monograph. Bethesda, MD: National Cancer Institute; 2005.
5. Li FP, Fraumeni JF Jr,. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J Natl Cancer Inst. 1969; 43: 1365-1373.
6. Li FP, Fraumeni JF Jr,. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969; 71: 747-752.
7. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990; 250: 1233-1238. (Pubitemid 120031831)
8. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003; 63: 6643-6650. (Pubitemid 37322942)
9. Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 Version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol. 2009; 27: e108-e109; author reply e110.
10. Bougeard G, Sesboue R, Baert-Desurmont S, et al. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet. 2008; 45: 535-538.
11. Lalloo F, Varley J, Ellis D, et al. Prediction of pathogenic mutations in patients with early onset breast cancer by family history. Lancet. 2003; 361: 1101-1102. (Pubitemid 36369565)
12. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009; 27: 1250-1256.
13. Achatz MI, Hainaut P, Ashton-Prolla P,. Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening? Lancet Oncol. 2009; 10: 920-925.
14. Hainaut P, Hollstein M,. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000; 77: 81-137. (Pubitemid 29439303)
15. Hafsi H, Hainaut P,. Redox control and interplay between p53 isoforms: roles in the regulation of basal p53 levels, cell fate and senescence [published online ahead of print May 4, 2011]. Antioxid Redox Signal. 2011.
16. Olivier M, Petitjean A, Marcel V, et al. Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther. 2009; 16: 1-12.
17. Scian MJ, Stagliano KE, Anderson MA, et al. Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol. 2005; 25: 10097-10110. (Pubitemid 41572755)
18. Strano S, Dell'Orso S, Di Agostino S, Fontemaggi G, Sacchi A, Blandino G,. Mutant p53: an oncogenic transcription factor. Oncogene. 2007; 26: 2212-2219. (Pubitemid 46536646)
19. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007; 28: 622-629. (Pubitemid 46744292)
20. Surveillance, Epidemiology, and End Results (SEER) Program. SEER Limited-Use Data (1975-2005) [released April 2008; based on the November 2007 submission]. Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; 2008.
21. Ries LA, Smith MA, Gurney JG, et al, eds. SEER Cancer Statistics Review. Cancer Incidence and Survival Among Children and Adolescents. NIH Publ. No. 99-4649. Bethesda. MD: SEER Program, National Cancer Institute; 1999.
22. Zippin C, Lum D, Hankey BF,. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer. 1995; 76: 2343-2350.
23. Fritz A, Jack A, Parkin DM, et al. eds. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
24. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P,. International Classification of Childhood Cancer, third edition. Cancer. 2005; 103: 1457-1467. (Pubitemid 40410743)
25. Zeger SL, Liang KY,. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986; 42: 121-130.
26. Diller L, Sexsmith E, Gottlieb A, Li FP, Malkin D,. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest. 1995; 95: 1606-1611.
27. Hwang SJ, Lozano G, Amos CI, Strong LC,. Germline p53 mutations in a cohort with childhood sarcoma: sex differences in cancer risk. Am J Hum Genet. 2003; 72: 975-983. (Pubitemid 36403315)
28. Toguchida J, Yamaguchi T, Dayton SH, et al. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med. 1992; 326: 1301-1308.
29. Lopez-Guerrero JA, Machado I, Scotlandi K, et al. Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors. Int J Cancer. 2011; 128: 1139-1150.
30. Neilsen PM, Pishas KI, Callen DF, Thomas DM,. Targeting the p53 pathway in Ewing sarcoma [serial online]. Sarcoma. 2011; 2011: 746939.
31. Donehower LA, Harvey M, Vogel H, et al. Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog. 1995; 14: 16-22.
32. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994; 4: 1-7.
33. Lang GA, Iwakuma T, Suh YA, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004; 119: 861-872. (Pubitemid 40017691)
34. Figueiredo BC, Sandrini R, Zambetti GP, et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet. 2006; 43: 91-96. (Pubitemid 43099998)